Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study

Yuichiro Ogura, Hiroko Terasaki, Fumi Gomi, Mitsuko Yuzawa, Tomohiro Iida, Miki Honda, Koichi Nishijo, Olaf Sowade, Tetsushi Komori, Ursula Schmidt-Erfurth, Christian Simader, Victor Chong, VIEW 2 Investigators, Yuichiro Ogura, Hiroko Terasaki, Fumi Gomi, Mitsuko Yuzawa, Tomohiro Iida, Miki Honda, Koichi Nishijo, Olaf Sowade, Tetsushi Komori, Ursula Schmidt-Erfurth, Christian Simader, Victor Chong, VIEW 2 Investigators

Abstract

Background/aims: To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial.

Methods: In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after 3 monthly injections; or 0.5 mg ranibizumab every 4 weeks (Rq4). Main efficacy outcomes included vision maintenance and best-corrected visual acuity (BCVA) at week 52.

Results: At week 52, all Japanese patients in the IVT-AFL groups (n=70) maintained vision, compared with 96% of Japanese patients (n=23/24) treated with ranibizumab. Japanese patients in all treatment groups showed improvement in BCVA after treatment. The Rq4, 2q4 and 2q8 groups experienced similar gains in BCVA from baseline. The 0.5q4 group had higher gains due to an unexpected drop in BCVA between screening and baseline. Central retinal thickness and mean area of choroidal neovascularisation decreased in all treatment groups with similar magnitude. Ocular treatment-emergent adverse events were balanced across treatment groups.

Conclusions: IVT-AFL was effective and well tolerated in Japanese patients. Outcomes in this population were consistent with those in the overall VIEW 2 population.

Trial registration number: NCT00637377.

Keywords: Angiogenesis; Clinical Trial; Macula; Neovascularisation; Retina.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Patient disposition.
Figure 2
Figure 2
Best-corrected visual acuity (BCVA) results. (A) Mean change from baseline; (B) mean absolute score from screening.
Figure 3
Figure 3
Central retinal thickness (CRT) results: mean change from baseline.

References

    1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48.
    1. Bird AC. The Bowman lecture. Towards an understanding of age-related macular disease. Eye (Lond) 2003;17:457–66.
    1. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008;115:1376–81, 1381.
    1. Oshima Y, Ishibashi T, Murata T, et al. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol 2001;85:1153–7.
    1. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15–22.
    1. Mori K, Horie-Inoue K, Gehlbach PL, et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology 2010;117:928–38.
    1. Uyama M, Takahashi K, Ida N, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol 2000;84:1018–23.
    1. Kawasaki R, Wang JJ, Amirul FM, et al. Is bilateral age-related macular degeneration less common in Asians than Caucasians? Ophthalmic Epidemiol 2011;18:253–8.
    1. Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012;32:1250–9.
    1. Matsumiya W, Honda S, Kusuhara S, et al. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol 2013;13:10.
    1. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012;379:1728–38.
    1. Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 2010;51:5914–19.
    1. Gotoh N, Nakanishi H, Hayashi H, et al. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;147:1037–41, 1041.
    1. Suzuki M, Gomi F, Sawa M, et al. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Jpn J Ophthalmol 2010;54:124–8.
    1. Tano Y, Ohji M. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88:309–16.
    1. Tano Y, Ohji M. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol 2011;89:208–17.
    1. Basic principles on Global Clincal Trials. http://www pmda go jp/kijunsakusei/file/guideline/new_drug/GlobalClinicalTrials_en pdf.
    1. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122–9.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться